Literature DB >> 27768834

Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.

Berna Akıncı Özyürek1, Özlem Özmen2, Tuğçe Şahin Özdemirel1, Yurdanur Erdoğan1, Bekir Kaplan3, Tuğba Kaplan4.   

Abstract

The aim of this study was to evaluate the relationship of the pre-treatment blood neutrophil/lymphocyte count ratio (NLR) with the maximum standard uptake value (SUVmax) of primary masses on positron emission tomography/computed tomography (PET/CT) taken before treatment in patients diagnosed with malignant pleural mesothelioma (MPM) and to evaluate the contribution to prognosis. A retrospective evaluation was made of 73 patients diagnosed with MPM in our hospital between January 2006 and January 2014. The SUVmax value of the primary mass on pre-treatment PET/CT, the haemogram parameters (Hb, Hct, NLR, MPV, PLT) at the time of diagnosis, the progression history, the date of the final visit, and the date of death of exitus patients was recorded from patient files PET/CT. The study group comprised 37 males (50.7%) with a mean age of 56.1 ± 11.4 years. The median survival time of these patients was 13 months. The survival time of the patient group aged <55 years was significantly longer (P = .006). Although the survival time of patients with NLR < 3 and SUVmax < 5 was longer, the difference was not statistically significant (P = .63, P = 0.08). A statistically significant difference was determined between the mean (or median) SUVmax values of the patient groups with NLR < 3 and NLR ≥3 (P = .019) with the SUVmax value of the NLR < 3 group found to be low. In conclusion, in patients with MPM, NLR ≥3 and high SUVmax values at the time of diagnosis can be considered an indicator of poor prognosis but are not a guide in the prediction of progression.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  FDG PET/CT; NLR; SUVmax; malignant mesothelioma

Mesh:

Substances:

Year:  2016        PMID: 27768834     DOI: 10.1111/crj.12574

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  2 in total

Review 1.  The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review.

Authors:  Silvia Taralli; Romina Grazia Giancipoli; Carmelo Caldarella; Valentina Scolozzi; Sara Ricciardi; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

Review 2.  Prognostic value of maximum standard uptake value, metabolic tumour volume, and total lesion glycolysis of 18F-FDG PET/CT in patients with malignant pleural mesothelioma: a systematic review and meta-analysis.

Authors:  Weibo Wen; Dongyuan Xu; Yongnan Piao; Xiangdan Li
Journal:  Cancer Cell Int       Date:  2022-02-03       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.